MEAF6

Across TCGA pan-cancer cohorts, MEAF6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEAF6 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MEAF6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MEAF6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where MEAF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.903	0.770	.008	24	view →
UCEC	OS	Median	III,IV	0.494	1.000	.016	16	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	14	view →
PDAC	OS	Median	IV	0.491	0.836	.024	3	view →
LSCC	OS	Median	All	1.000	0.813	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEAF6–CCRCC (OS)

Open the CCRCC breakdown →